º

October 20-21, 2015San Francisco

14TH ANNUAL

-1-

Why Attend BIO Investor Forum?INDEPENDENT HOST — One of the only independent investor conferences dedicated to helping early-stage biotech companies find sources of capital.

EFFICIENT PARTNERING — Ideal venue for investors and company executives to discuss financial and strategic business issues affecting investment in biotech companies and explore potential partnerships and business collaborations to fuel research and development for promising innovation.

GLOBAL SCOPE — Attracts healthcare venture capital and public market investors and research analysts as well as business development executives from leading global pharmaceutical and biotechnology companies.

COMPELLING VOICES — Offers ample networking opportunities, informative therapeutic and business workshops, and presentations from up-and-coming companies.

New in 2015The BIO SPARK Showcase Event provides an excellent opportunity for academic researchers in the SPARK network to showcase drug development programs that are ready for partnering or venture funding. The symposium will feature a keynote speech by Dr. Daria Mochly-Rosen, SPARK Director and George D. Smith Professor in Translational Medicine, Stanford University School of Medicine.

BIO and FierceBiotech will celebrate the 15 privately held drug developers and platform biotechs with the potential to have a huge impact on the treatment of human diseases.

AT STANFORD

SPARK

-2-

Advisory Committee

Cayce DentonVice President, TPG Biotech

John ChambersVice-Chairman and Head of Healthcare Investment Banking, ROTH Capital Partners

Jit PatelVice President of Research Business Development, JDRF

David WoodhouseChief Financial Officer, NGM Biopharmaceuticals

Asish K. Xavier, PhD Vice President, Venture Investments, J&J Development Corporation

Vikas Goyal, MBAPrincipal, S.R. One, Limited

Charlotte HubbertProgram Investment Officer, Program Related Investments, Bill and Melinda Gates Foundation

Stephen T. IsaacsPresident and CEO, Aduro Biotech

Jason HaflerDirector of Investments, Sanofi-Genzyme BioVentures

John PoulosVice President, Head of Licensing and Acquisitions, AbbVie

Jennifer Landress, CMPSenior Vice President and Chief Operating Officer, Biocom

Paulina HillPrincipal, Polaris Partners

Julie PapanekPrincipal, Canaan Partners

Sara RadcliffePresident & CEO, California Life Sciences Association (CLSA)

Arlene MorrisCEO, Willow Advisors

-3-

Therapeutic Panel TopicsReport from the Frontier: Emerging Oncology Trends Bridging ASCO to ASHTuesday, October 20, 10:30 a.m. - 11:25 a.m.| 4th Floor, Mission RoomIf you missed the most important oncology event so far this year, this panel will address the key takeaways and what’s new since then. Just how important is PD-1 in your portfolio? CAR-T: is it still the game changing technology since 2014? What role will combination therapies play going forward into 2016? Will dendritic cell therapies maintain relevance in the immuno-oncology space? What does the ideal immuno-oncology portfolio look like? Will we continue to see partnering of assets amongst emerging biotechs?

Moderator: • Jeff Smith, PhD, Vice President, Investment Banking, H.C. Wainwright & Co.

Panelists:• Louis J. DeGennaro, PhD, President & CEO, The Leukemia & Lymphoma Society (LLS)• Olivier Lesueur, Managing Director, BIONEST Partners• Ben Thorner, VP Business Development & Licensing, Head of North American Innovation Hubs,

Merck Research Laboratories• Geeta Vemuri, PhD, Managing Partner, Baxalta Ventures• Jeffrey Wolf, Founder & CEO Heat Biologics

Precision Medicine: Leveraging National Genomic Databases for Therapy Development (U.S., UK, Iceland)Tuesday, October 20, 9:00 a.m. - 9:55 a.m.| 4th Floor, Mission RoomAs the price point for full genome analysis falls through the $1,000 per person milestone, national efforts are ramping up for large studies that should enable much more personalized therapies. This data should accelerate drug development by clarifying genetic targets and the most appropriate patient sub-groups for clinical trials. The US’s NIH is planning a million-person database, the UK’s NHS is already recruiting a 100,000 genome collection, and Iceland’s deCODE initiative has already produced findings from its 160,000 person database. This panel will discuss the variety of strategies drug/therapy developers can apply to leverage these infrastructure investments most effectively.

Moderator: • Esteban G. Burchard, MD, MPH, Professor of Medicine and Bioengineering and Therapeutic Sciences,

University of California, San Francisco; member of NIH Precision Medicine Initiative Working Group

Panelists:• Neil Campbell, President and Chief Executive Officer, Helomics• Andrew May, D.Phil., Chief Scientific Officer, Caribou Biosciences• Matthew Scholz, CEO, Immusoft• Pamela Sklar, MD, PhD, Chief, Division of Psychiatric Genomics, Icahn School of Medicine at Mount Sinai • Hannes Thor Smárason, Co-Founder and COO, WuXi NextCODE

-4-

Therapeutic Panel Topics

Stretching Your Dollar: Methods and Tools for Increasing the Productivity of Clinical TrialsWednesday, October 21, 10:30 a.m. - 11:25 a.m.| 4th Floor, Mission RoomRecent Tufts data show clinical trials typically take nearly twice as long to complete enrollment as predicted at launch and 48% of trial sites miss enrollment targets. Delays in trials shrink the returns from patent exclusivity and increase R&D costs. New methods such as adaptive and batch trial designs, as well as explosive growth in digital tools, such as Apple’s ResearchKit, have transformed the trial design choices available. These innovations, and others, provide new levers for boosting productivity of clinical trials—with positive implications for improving cash burn rates and accelerating speed-to-market.

Moderator: • Sastry Chilukuri, Partner, McKinsey & Company

Panelists:• Noah Craft MD, PhD, DTM&H, Co-Founder & CEO, Science 37, Inc.• Avi Kulkarni, PhD, Managing Director and Senior Vice President, Quintiles Advisory Services• Michael V. McConnell, MD, MSEE, Professor of Medicine, Director of Cardiovascular Health Innovation

and PI of the MyHeart Counts mHealth research study, Stanford School of Medicine• Matt Noble, Senior Director, Product Management, Medidata Solutions• Komathi Stem, Strategic Innovation Leader, Genentech (invited)

Policy Outlook—Valuation Model Implications of 21st Century Cures, IP Reform, TPP, and PDUFA VITuesday, October 20, 2:00 p.m. - 2:55 p.m.| 4th Floor, Mission Room2015 is producing more legislative and regulatory policy changes that apply to drug development than the industry has seen in several years. Each shift in exclusivity rules, patient-centered endpoints, patent challenge rules, or FDA application policies can dramatically affect how you—and your investors—value your therapeutic pipeline. Join this panel moderated by a BIO policy expert on whether some or all these proposals will actually take effect.

Moderator: • Jeanne Haggerty, SVP Federal Government Relations, BIO

Panelists:• Paul J. Hastings, Chairman & CEO, OncoMed Pharmaceuticals• Elizabeth Krutoholow, Analyst, Bloomberg Intelligence• Andrew N. Merickel, PhD, Partner, Knobbe Martens• Sara Radcliffe, MPH, President & CEO, California Life Sciences Association

(Speakers added daily. Please visit www.bio.org/investorforum for most up to date program and confirmed presenters).

-5-

Business Panel Topics

Investor Management Lessons of Fierce 15 AlumniTuesday, October 20, 4:30 p.m. - 5:25 p.m.| 4th Floor, Mission RoomEach year FierceBiotech’s John Carroll has identified the “fiercest” private companies most likely to create dramatic growth for their investors. As many of those private companies went public, those CEOs’ relationships with their Boards evolved as pure venture investors made their exits. What are the most important factors investors look for in company management teams—and vice versa? How closely does the board align with company management to make an attractive investment offering? And what makes the investment banks see real value when looking at a potential IPO? Join past Fierce 15 winners as they discuss what they have learned.

Moderator: • John D. Carroll, Editor-in-Chief, FierceBiotech

Panelists:• Mark A. Goldsmith, MD, PhD, Founding President, CEO, and Board Director, REVOLUTION Medicines• Thomas E. Hughes, PhD, Zafgen (invited)• Stephen T. Isaacs, Chairman, President, and CEO, Aduro Biotech• Jeff Junker, President, NGM• William Lis, CEO, Portola Pharmaceuticals

Venture Capital Funding Trends: BIO Analysis of Ten Years of Investment and the Gaps that AppearWednesday, October 21, 9:00 a.m. - 9:55 a.m.| 4th Floor, Mission RoomBIO’s recent analysis of investment and deal trends across the past decade for emerging therapeutic companies found three remarkable gaps between where VCs have placed their investments and what might be expected by biotech CEOs. First, despite a remarkable growth in the number of start-ups, there appears to be a bottleneck of about 65 Series A rounds made per year—why? Second, the period sees a shift in popularity away from common chronic diseases toward rare diseases and oncology—how permanent is this therapeutic bias? Third, crossover investors are supporting more private companies earlier, but the total amount of Series A funding per year appears much flatter than the rocketing total of IPO value creation—will that venture money come back or are good startups getting frozen out? Learn from the investors making the individual decisions and how they see these trends continuing or changing in the future.

Moderator: • Michael J. O’Donnell, Partner, Morrison & Foerster

Panelists:• Lindy Fishburne, Executive Director, Breakout Labs; SVP for Investments, Thiel Foundation• Charlotte Hubbert, Program Investment Officer, Venture Investing, The Bill & Melinda Gates Foundation• Camille Samuels, Partner, Venrock• David Thomas, CFA, Senior Director, Industry Research and Policy Analysis, BIO• Ilan Zipkin, PhD, Senior Investment Director, Takeda Ventures

-6-

Business Panel Topics

BioCentury Presents: Courting Crossover InvestorsWednesday, October 21, 2:00 p.m. - 2:55 p.m. | 4th Floor, Mission RoomThe participation rate of crossover investors in biotech venture funding rounds has been growing at more than 50% per year since 2012 with anecdotal information suggesting a near necessity of such involvement to maximize a company’s IPO performance. BioCentury will provide new data to quantify the impact of crossover fund involvement as well as foster a panel discussion of the “do’s and don’ts” of managing relationships with such investors.

Moderator: • Steve Edelson, Senior Editor, Finance, BioCentury Publications, Inc.

Panelists:• James Healy, MD, PhD, General Partner, Sofinnova Ventures• Nathan Hubbard, Vice President Transactions, Oncology and Diagnostics, Eli Lilly and Company• Oleg Nodelman, Founder and Managing Director, EcoR1 Capital• Jonathan Norris, Managing Director, Silicon Valley Bank• Dinesh V. Patel, PhD, President & CEO, Protagonist Therapeutics

Market Outlook—Status of the IPO Appetite, M&A, Foreign Shocks, and Higher Interest Rates?Wednesday, October 21, 4:30 p.m. – 5:30 p.m.| 4th Floor, Mission Room While the appetite for new IPOs remains strong and cash is still flowing freely in the capital intensive biotech sector, concerns over valuation have the public markets on high alert. Investment banks are competing for the next biggest IPO with less clinical evidence in place up front. As M&A among payers and among biopharmas start a new round of consolidation, what does all this mean for privately held companies? Global economic factors have had a serious impact across all sectors, but how will biotech be affected? Has the biotech sector’s resilience strengthened since the last downturn? This panel of diverse experts will discuss what we can learn from history and where the market is crossing a new frontier.

Moderator: • Brian Hagerty, Senior Director, Capital Markets, New York Stock Exchange

Panelists:• John Chambers, Vice-Chairman and Head of Healthcare Investment Banking, ROTH Capital• Margarita Chavez, Director, Venture & Early Stage Collaborations, AbbVie Biotech Ventures• Asthika Goonewardene, Senior Biotech Analyst, Bloomberg Intelligence• David Woodhouse, PhD, Chief Financial Officer, NGM Biopharmaceuticals

-7-

Fireside Chats at Plenary Luncheons

5AM VenturesAquilo CapitalAstellas Venture ManagementATEL VenturesATEM CapitalAvalon VenturesBaxter VenturesBay City CapitalBill & Melinda Gates FoundationBioEngine Technology DevelopmentBioInnovation CapitalBiomark CapitalBrace Pharma CapitalBridge BankBVF PartnersCanaan PartnersChina Health Industry Capital Investment China Healthcare Industrial Capital Fund

Management (Shanghai) Co., LtdClaremont Creek VenturesClaremont Creek Ventures Codon CapitalCRG LPDiamond BioFund Inc.EcoR1 CapitalFinance Technology LeverageFrazier Healthcare PartnersGE Capital, Life Sciences

GE VenturesHercules Technology Growth CapitalInventis Investment Holdings (China) Juvenile Diabetes Research Foundation

InternationalJohnson & Johnson Innovation - JJDCJump CapitalKearny Venture PartnersLife Science Angels Lincoln Park CapitalLongitude CapitalLumira CapitalMBL Venture Capital Co., LtdMedimmune Ventures, IncMill Valley Partners MIT AngelsMitsui & Co. Global InvestmentMoore Venture PartnersNanoDimesionNew Leaf Venture PartnersNovo Ventures Oberland CapitalOrbiMed AdvisorsOxford Finance LLCPalo Alto InvestorsPharmaFund LLPPlatform HoustonPrecision Bioventures

Sacramento Angels and Chemical Angels Network

Sanderling VenturesSolar CapitalSR OneSynthesis CapitalTavistockTech Coast AngelsThe Angels’ ForumThe University of CaliforniaVantagePoint Capital PartnersVenrockVersant VenturesVertex Venture HoldingsVivo CapitalWRF Capital

*As of 9/28/2015

Below is the preliminary list of 2015 participating investors for the BIO Investor Forum.

NEW!

BIO is pleased to feature Robert Nelsen and James Noble as this year’s fireside chat speakers! Fireside chats feature candid discussions between biopharma senior executives and industry experts. Hear about recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2016.

Participating Investors*

Robert T. Nelsen ARCH Venure PartnersCo-Founder and Managing Director

Moderated by: Matthew Rossiter, Partner, Fenwick & West

Wednesday, October 21, 12:30-1:25 p.m

James Noble AdaptimmuneCEO

Moderated by: Tony Gibney, Managing Director, Leerink Partners LLC

Tuesday, October 20, 12:30-1:25 p.m.

-8-

Presenting Companies

The following is the list of presenting companies for the 14th Annual BIO Investor Forum. Presenters will consist of Discovery Companies (under 25M raised to date in Seed or Series A financing rounds), established private companies (over 25M raised and in Series B and above) and emerging public companies.

CARDIOVASCULARArmetheonRECARDIO Inc.Resverlogix Corp. (TSX: RVX)

CNS/NEUROLOGICALAgeneBioAgilis BiotherapeuticsAmarantus BioScience Holdings, Inc.

(OTCQX: AMBS)Cerecor Inc. (NASDAQ: CERC)ComentisEmbera NeuroTherapeutics, Inc.Impel NeuroPharmaIxchel Pharma LLCKineMed, Inc.NeuroGenetic PharmaceuticalsProbiodrug (Euronext: PBD)Trigemina, Inc.WinSanTorZynerba Pharmaceuticals (NASDAQ:

ZYNE)DERMATOLOGY

MiNDERA Corp.RXi Pharmaceuticals Corporation

(NASDAQ: RXII)TransDerm

DIAGNOSTICSAmadixBiocept (NASDAQ: BIOC)BioMarker StrategiesINanoBio Inc.Mediomics, LLCMoleculera LabsOncoCyte CorporationProvista Diagnostics, Inc.

DRUG DELIVERYGlide TechnologiesNeos Therapeutics (NASDAQ: NEOS)Portal Instruments

GASTROINTESTINALAvexegen TherapeuticsLiveLeaf BioScienceProtagonist Therapeutics Inc.RDD Pharma TaiwanJ Pharmaceuticals

GENE/CELL THERAPYBenitec Biopharma (ASX: BLT)MultiVir Inc.Opexa Therapeutics (NASDAQ:

OPXA)IMMUNOLOGY

Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH)

Kineta, Inc.Oxis International, Inc. (OTC: OXIS)RuiYi

INFECTIOUS DISEASESC3 Jian, Inc.ContraFect (NASDAQCM: CFRX)

ContraVir Pharmaceuticals (NASDAQ: CTRV)

CurzaInvVax, Inc.Matinas BioPharma Holdings, Inc.

(OTCQB: MTNB)Rebiotix Inc.TheraBiol, Inc.Valley Fever Solutions

INFLAMMATIONAbGenomics International Inc.ComplexaCorbus Pharmaceuticals Holdings, Inc.

(NASDAQ: CRBP)Relburn-Metabolomics, Inc.

MEDICAL DEVICESBionik Laboratories Corp. (OTCBB:

BNKL)MedLumics S.L.

METABOLIC DISEASESGalmed Pharmaceuticals (NASDAQ:

GLMD)MAX BioPharmaSensor Pharmaceuticals, Inc.Thetis Pharmaceuticals LLCThrasos Therapeutics Inc.Viking Therapeutics, Inc. (NASDAQ:

VKTX)Xeris Pharmaceuticals, Inc.Zafgen (NASDAQ: ZFGN)

NON-PROFIT/ADVOCACY ORGANIZATION

The National MS Society/Fast Forward, LLC

Trade Office of Ecuador in Los Angeles

ONCOLOGYAbVitro Inc.AhR Pharmaceuticals, Inc.Aptose Biosciences Inc. (NASDAQ;

TSX: APTO; APS)ARMO BioSciencesAtossa Genetics Inc. (NASDAQ:

ATOS)Avelas Biosciences, Inc.Batu BiologicsBioCurity Holdings, Inc. Bio-Path Holdings, Inc. (NASDAQ:

BPTH)BriaCell Therapeutics Corp. (OTCQB:

ANCCF)Cantex Pharmaceuticals, Inc.Capella Therapeutics, Inc.Cellectar Biosciences (NASDAQ:

CLRB)Colby Pharmaceutical CompanyCold Genesys, Inc.Cormorant PharmaceuticalsCritical Outcome Technologies Inc.

(TSXV; OTCQB: COT; OTCQF)Curis, Inc. (NASDAQ: CRIS)EnGeneIC Ltd.

Euclises Pharmaceuticals, Inc.Felicitex TherapeuticsGenSpera, Inc. (OTCQB: GNSZ)Geron Corporation (NASDAQ: GERN)Helix Biopharma Corp. (TSX: HBP)Helomics CorporationImmunGene, Inc.Immunovaccine Inc. (TSX; OTCQX:

IMV; IMMVF)MEI Pharma, Inc. (NASDAQ: MEIP)Meryx Inc.Monopar TherapeuticsNavidea Biopharmaceuticals (NYSE

MKT: NAVB)Neovia Oncology LtdOncoceutics, Inc.Oncolytics (NASDAQ: ONCY)OncoSec Medical, Inc. (NASDAQ:

ONCS)PCI Biotech (OSB: PCIB)Rexahn Pharmaceuticals (NYSE MKT:

RNN)Sellas Life Sciences GroupSolaranRx, Inc.Spectrum Pharmaceuticals

(NASDAQGS: SPPI)Susavion Biosciences, Inc.Sutro BiopharmaThe Leukemia & Lymphoma SocietyTokai Pharmaceuticals, Inc. (NASDAQ:

TKAI)Xcovery

OPHTHALMOLOGYActiveSite Pharmaceuticals, Inc.Isarna TherapeuticsMakindus, Inc.Nicox SA (Euronext Paris: COX)NovaBay Pharmaceuticals (NYSE:

NBY)Tyrogenex

ORPHAN/RARE DISEASESAntegrin Therapeutics, Inc.Aten Porus LifesciencesCatalyst Pharmaceuticals, Inc.

(NASDAQ: CPRX)DelMar Pharmaceuticals, Inc. (OTCQX:

DMPI)Fennec Pharmaceuticals (TSX;

OTCQB: FRX; FENCF)Global Blood Therapeutics (NASDAQ:

GBT)Laurent PharmaceuticalsMast Therapeutics, Inc. (NYSE MKT:

MSTX)Newron Pharmaceuticals SpA (SIX:

NWRN)Ocera Therapeutics, Inc. (NASDAQ:

OCRX)SavaraThrombotargets EuropeTrue North Therapeutics, Inc.

OTHERAmunixAurinia Pharmaceuticals (NASDAQ:

AUPH)Kadmon CorporationRichcore LifesciencesSynthetic Biologics, Inc. (NYSE MKT:

SYN)Whole Biome Inc.

PAIN MANAGEMENTDURECT Corporation (NASDAQ:

DRRX)Nuvo Research Inc. (TSX: NRI)Relmada Therapeutics (OTCQB:

RLMD)PLATFORM FOR THERAPEUTICS

Cloud PharmaceuticalsCyclica Inc.Encycle TherapeuticsPronutria BiosciencesResilience Therapeutics, Inc.Symic BiomedicalTransparency Life Sciences, LLC

REGENERATIVE MEDICINEAegle Therapeutics CorporationECBioHistogenics Corporation (NASDAQ:

HSGX)Magnus Life ScienceSilver Creek Pharmaceuticals, Inc.ViaCyte

REPRODUCTIVE/SEXUAL HEALTH

Apricus Biosciences, Inc. (NASDAQ: APRI)

Palatin Technologies, Inc. (NYSE MKT: PTN)

RESPIRATORYAxikin Pharmaceuticals Inc.Biomay AGCortex Pharmaceuticals, Inc.

(NASDAQ; OTCQB: CORX)LA BioMedPulmatrix (NASDAQ: PULM)Silurian Pharmaceuticals

TOOLS/DRUG DEVELOPMENT SUPPORT TECHNOLOGY

Protein Dynamic Solutions LLCTwist Bioscience, Corp

VACCINESAdjuvance TechnologiesAurora BioPharma, Inc.Protein SciencesProventus Bio

*As of 9/28/2015

2014 Meeting Directionality

-9-

One-on-One PartneringTM Meetings

BIO One-on-One Partnering™ is the most efficient and economical way to develop new business relationships. This interactive environment allows you to increase your meeting productivity, discover new investment and licensing opportunities and expand your business partnerships worldwide. Using this online tool, you will be able to:

Pre-schedule 25-minute, private 1x1 meetings;

Search company and investor profiles, drug assets, products and services in the biotech and pharmaceutical industries;

Evaluate potential collaborations and funding opportunities with participating companies; and

Communicate directly with prospective investors and senior management.

For questions about the BIO One-on-One Partnering™ System, please contact biopartnering@bio.org.

More than 1,400 One-on-One meetings scheduled at BIF through BIO One-on-One Partnering™ in 2014

400+ companies200+ investors

Company to Company

34%

Investors to Company

24%

Company to Investors

40%

Investors to Investors

2%

Attendee Profile

-10-

Audience Demographics

“ A fantastic way to meet with many potential investors and business partners. This way, I easily saved on 8-10 separate business trips.”

Over 40% of attendees were C-level Executives

3D130/170/20/35

Investors 34%

BD/Licensing 15%

Other 18%

Biotech Execs 33%

Investor Profile

3D130/170/20/35

Sell-Side Research: 8%

Venture Capitalist 60%

Portfolio Manager

9%

Buy-Side Research: 8%

Institutional Investor: 7%

Other 8%

-11-

Registration

BIO offers a number of ways for conference attendees to save money on their registration fees. Discounted rates apply to the following:

Biotech companies that have raised less than $25 million in capital.

Presenting companies bringing three or more attendees.

Companies bringing more than two employees.

Corporations or other entities that use biotechnology or related technologies for research and development of products or information.

Academic institutions.

Qualified institutional and venture investors are eligible for complimentary registration.

Hotel/Venue InformationParc 55 San Francisco, A Hilton Hotel 55 Cyril Magnin Street San Francisco, CA 94102 (415) 392-8000Book your room today to also receive the discounted room rate. Reservation requests are based on availability, space is limited.

Register today at bio.org/investorforum

3

3

3

3

3

SponsorsSupporting Bank SponsorsRegional Co-Hosts

Industry Supporter

BIO Double Helix Sponsors BIO Helix Sponsors

Conference Supporters

Media Partners

Contact us today for a tailored sponsorship package that will meet your business objectives. Contact Fabien Rabanal at frabanal@bio.org or call (202) 962-9278. For more information on BIO sponsorships, please visit www.bio.org/sponsor

Join the conversation:Learn more about Biotechnology at bio.orgEngage with the Biotech Community at BIOtech-NOW.orgFollow us on Twitter @bio1x1Become a fan on Facebook (facebook.com/IAmBiotech)

®

E x e c u t i v e & B o a r d S e a r c h

Strategic Advisors, Inc.Tiberend